Stock VXRT VAXART, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Vaxart, Inc.

Equities

VXRT

US92243A2006

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.7097 USD +7.79% Intraday chart for Vaxart, Inc. -6.07% +23.90%
Mar. 14 Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 14 Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024

Evolution of the average Target Price on Vaxart, Inc.

Price target over the last 5 years

History of analyst recommendation changes

4f7bdcf3e5c87ca8f5d475b1.l8ebeV8jVhK5haGb-N_HHXRN2UBHWGYO6EZdaev6vdQ.46jKNjNoOUDr99KiirySSAYloXIqASNLrDUcHNqo263u6uMvDkIzfuv95A~6c2f26e93012d171ea81fca1753f53c1

Analyst Recommendations on Vaxart, Inc.

B. Riley Upgrades Vaxart to Buy From Neutral, Lifts PT to $2 From $1.50 MT
Cantor Fitzgerald Adjusts Price Target on Vaxart to $4 From $6, Maintains Overweight Rating MT
B. Riley Lowers Vaxart's PT to $1.50 From $6, Reflecting More Conservative Estimate of Ramp-up of Norovirus; Keeps Neutral Rating MT
Cantor Fitzgerald Adjusts Vaxart's Price Target to $8 From $11, Reiterates Overweight Rating MT
B. Riley Trims Vaxart's Price Target to $6 from $7 to Reflect Modest Increased Long Term Cost of Capital Amid Current Macro Conditions; Keeps Neutral Rating MT
B. Riley Lowers Vaxart's Price Target to $7 from $9 to Reflect Long Term Higher Cost of Capital Amid Current Macro Conditions, Keeps Neutral Rating MT
Jefferies Analyst Starts Vaxart at Buy, Adjusts Price Target to $12 From $13 MT
Cantor Fitzgerald Starts Vaxart at Overweight With $15 Price Target MT
VAXART : B. Riley Downgrades Vaxart to Neutral from Buy, Lowers PT to $9 from $13 on 'Underwhelming' Immunogenicity Dataset, Challenging Near-term Catalyst Setup MT
VAXART : Jefferies Initiates Coverage on Vaxart With Buy Rating, $13 Price Target MT
Vaxart : Shares Jump After Piper Sandler Starts Coverage With Overweight Rating MT
VAXART : Piper Sandler Starts Vaxart at Overweight With $18 Price Target MT
VAXART : B. Riley Lowers Vaxart's Price Target to $13 from $16, Keeps Buy Rating MT
VAXART : B. Riley Adjusts Vaxart PT to $16 From $22, Maintains Buy Rating MT
Vaxart, Inc. Announces its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.7097 USD
Average target price
5 USD
Spread / Average Target
+604.52%
High Price Target
8 USD
Spread / Highest target
+1,027.24%
Low Price Target
2 USD
Spread / Lowest Target
+181.81%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Vaxart, Inc.

B. Riley
Cantor Fitzgerald
Jefferies & Co.
Piper Sandler

Ratings for Vaxart, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. VXRT Stock
  4. Consensus Vaxart, Inc.